ATE456048T1 - Verfahren zur beurteilung von immunreaktionen - Google Patents

Verfahren zur beurteilung von immunreaktionen

Info

Publication number
ATE456048T1
ATE456048T1 AT05804838T AT05804838T ATE456048T1 AT E456048 T1 ATE456048 T1 AT E456048T1 AT 05804838 T AT05804838 T AT 05804838T AT 05804838 T AT05804838 T AT 05804838T AT E456048 T1 ATE456048 T1 AT E456048T1
Authority
AT
Austria
Prior art keywords
immune reactions
subset
assessing immune
immune reactivity
epitopes
Prior art date
Application number
AT05804838T
Other languages
English (en)
Inventor
Jacques Banchereau
John Connolly
Anna Palucka
Hideki Ueno
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Application granted granted Critical
Publication of ATE456048T1 publication Critical patent/ATE456048T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/10Libraries containing peptides or polypeptides, or derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
AT05804838T 2004-05-24 2005-05-24 Verfahren zur beurteilung von immunreaktionen ATE456048T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57391204P 2004-05-24 2004-05-24
PCT/US2005/018418 WO2005117996A2 (en) 2004-05-24 2005-05-24 Immune response assessment method

Publications (1)

Publication Number Publication Date
ATE456048T1 true ATE456048T1 (de) 2010-02-15

Family

ID=35463368

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05804838T ATE456048T1 (de) 2004-05-24 2005-05-24 Verfahren zur beurteilung von immunreaktionen

Country Status (9)

Country Link
US (1) US20060051358A1 (de)
EP (3) EP2253956A3 (de)
JP (2) JP2008507259A (de)
CN (1) CN1989410A (de)
AT (1) ATE456048T1 (de)
CA (1) CA2567491A1 (de)
DE (1) DE602005019054D1 (de)
ES (2) ES2390248T3 (de)
WO (1) WO2005117996A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228635A1 (en) * 2002-02-15 2003-12-11 Renovar, Inc. Cell proliferation assays and methods
GB0524866D0 (en) * 2005-12-05 2006-01-11 Univ Aberdeen Method of tolerisation
EP2128612B1 (de) * 2006-09-05 2011-03-30 Hvidovre Hospital Auf IP-10 basierende immunologische Überwachung
WO2012068474A2 (en) * 2010-11-19 2012-05-24 Rutgers, The State University Of New Jersey A high-throughput asseessment method for contact hypersensitivity
CN103495157B (zh) * 2013-09-26 2016-03-16 常州牛津石松生物科技有限公司 一种dc疫苗及其制备方法和应用
WO2015153969A1 (en) 2014-04-04 2015-10-08 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for t cell receptors
US9927443B2 (en) 2015-04-10 2018-03-27 Conquerab Inc. Risk assessment for therapeutic drugs
JP6100867B1 (ja) * 2015-11-06 2017-03-22 振武 曽 免疫状態の分析のための検査方法
WO2017095324A1 (en) * 2015-12-04 2017-06-08 Agency For Science, Technology And Research Clinical correlates of immunotherapy efficacy
US9903866B2 (en) 2016-04-05 2018-02-27 Conquerab Inc. Portable devices for detection of antibodies against therapeutic drugs
EP3873614A4 (de) * 2018-10-29 2022-09-07 Genocea Biosciences, Inc. Behandlungsverfahren
CN117106847A (zh) * 2020-03-09 2023-11-24 山东大学齐鲁医院 干细胞制剂的免疫调控功能的评估方法
CN118119846A (zh) * 2021-07-16 2024-05-31 医疗财团法人徐元智先生医药基金会亚东纪念医院 用于诊断轻度认知功能障碍的方法和试剂盒
CN115184614B (zh) * 2022-06-14 2023-11-03 北京大学 免疫效度或临床相对免疫效度在评价受试者的疫苗应答强度中的应用
CN116183933A (zh) * 2023-02-21 2023-05-30 上海市第一人民医院 生物标志物组合物及其在制备评价机体免疫功能的产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2189425A1 (en) * 1994-05-03 1995-11-09 Hans Michael Dosch Methods for controlling t lymphocyte mediated immune responses
ES2272074T3 (es) * 1998-01-19 2007-04-16 Florian Kern Procedimiento para la identificacion de fragmentos proteicos estimuladores de celulas t.
ATE437366T1 (de) * 1998-05-11 2009-08-15 Miltenyi Biotec Gmbh Verfahren zur direkten auswahl von antigen- spezifischen t-zellen
AU767391B2 (en) * 1998-10-05 2003-11-06 Genzyme Corporation Peptides related to an IGF-II-R epitope, polynucleotides encoding the peptides, and their use in immunomodulation
ATE345389T1 (de) * 1999-09-30 2006-12-15 Univ Washington Immunologisch relevante antigene aus herpes simplexvirus
GB0007088D0 (en) * 2000-03-23 2000-05-17 Torsana A S Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates
EP1359937A4 (de) * 2001-02-14 2004-07-28 Genzyme Corp Veränderte peptidliganden
GB0215710D0 (en) 2002-07-05 2002-08-14 Isis Innovation Diagnostic method

Also Published As

Publication number Publication date
CN1989410A (zh) 2007-06-27
EP1774332A4 (de) 2008-06-25
CA2567491A1 (en) 2005-12-15
WO2005117996A2 (en) 2005-12-15
JP2011250787A (ja) 2011-12-15
EP2184607B1 (de) 2012-07-11
ES2341723T3 (es) 2010-06-25
HK1143417A1 (en) 2010-12-31
EP2184607A1 (de) 2010-05-12
EP2253956A3 (de) 2011-07-06
EP1774332B1 (de) 2010-01-20
ES2390248T3 (es) 2012-11-08
EP1774332A2 (de) 2007-04-18
WO2005117996A3 (en) 2006-06-22
DE602005019054D1 (de) 2010-03-11
EP2253956A2 (de) 2010-11-24
US20060051358A1 (en) 2006-03-09
JP2008507259A (ja) 2008-03-13

Similar Documents

Publication Publication Date Title
ATE456048T1 (de) Verfahren zur beurteilung von immunreaktionen
MA29528B1 (fr) Agents de fixation
DE602005017781D1 (de) Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
ATE505489T1 (de) Tgf-beta-1-spezifische antikörper
ATE443260T1 (de) Kontrastmittel und verfahren zum imaging von naaldase oder psma
ATE528410T1 (de) Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration
DE602004030372D1 (de) Verfahren zur Bestimmung des relativen genetischen Risikos für Autismus
DE60139542D1 (de) Methoden zur herstellung humaner monoklonaler antikörper
ATE424560T1 (de) Marker für neuromyelitis optica
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
WO2010041149A3 (en) Methods and compositions for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
HUP0303655A2 (hu) Proliferatív ileitis elleni hatékonyabb vakcinák, előállításuk és alkalmazásuk
FI20011664A7 (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
FI20011671A7 (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
Lim et al. The relationship of organizational factors to employee health and overall effectiveness
ATE456666T1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
EA201100253A1 (ru) Глутаминилциклаза в качестве диагностического/прогностического индикатора нейродегенеративных заболеваний
ATE451618T1 (de) Verfahren zur identifizierung von epitopen in zusammenhang mit immunogenität bei biopharmazeutika
DE602005011642D1 (de) Bildgebung durch kohärente Streuung
WO2005040806A3 (en) Use of protein asc as a marker for breast cancer
DE602004026439D1 (de) Lp-pla2-aktivitätstest mit hohem durchsatz
SG142293A1 (en) Method for producing anti-idiotypic antibodies
ATE432469T1 (de) Auf immunreaktion gegen boris basierendes verfahren für den nachweis von krebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties